# Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

> **NCT04918823** · PHASE1,PHASE2 · COMPLETED · sponsor: **Boston Sight** · enrollment: 10 (actual)

## Conditions studied

- Ocular Surface Disease

## Interventions

- **DRUG:** Restasis

## Key facts

- **NCT ID:** NCT04918823
- **Lead sponsor:** Boston Sight
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-14
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918823, "Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04918823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*